Omeros adds Joseph Schocken to board of directors

Omeros Corporation expanded its Board of Directors to nine members and appointed Joseph Schocken as a director effective August 12, 2026.

Rhea-AI Filing Summary

Omeros Corporation expanded its Board of Directors to nine members and appointed Joseph Schocken as a director effective August 12, 2026. His initial term runs until the Company’s 2027 annual meeting of shareholders or earlier resignation or removal.

Schocken, 79, is a private investor and founder and president of Tranceka Capital, LLC, with a long history in investment banking and public-company leadership. He was also a driving participant in national economic policy discussions and the JOBS Act and currently serves as chairman of Taqtile, Inc.

Under Omeros’ non-employee director compensation policy, Schocken received a stock option to purchase 30,000 shares of common stock on his appointment date and will be covered by the Company’s standard director indemnification agreement. He joins the Board’s Audit Committee, and the Company states he has no disclosable material interests in related-party transactions.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Board size: 9 directors Stock option grant: 30,000 shares Director term end: 2027 annual meeting of shareholders +1 more

4 metrics

Board size 9 directors Number of directors after August 12, 2026 appointment

Stock option grant 30,000 shares Option to purchase common stock granted to Joseph Schocken on appointment

Director term end 2027 annual meeting of shareholders Scheduled expiration of Joseph Schocken’s initial board term

Age of new director 79 Age of Joseph Schocken at time of appointment

Key Terms

non-employee director compensation policy, indemnification agreement, Audit Committee, Item 404(a) of Regulation S-K

4 terms

non-employee director compensation policy financial

"Pursuant to our non-employee director compensation policy, Mr. Schocken was granted a stock option"

indemnification agreement regulatory

"Mr. Schocken will be indemnified by the Company pursuant to the terms of our standard form of director indemnification agreement"

An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.

Audit Committee financial

"The Board of Directors also appointed Mr. Schocken to the Audit Committee of the Board of Directors"

A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.

Item 404(a) of Regulation S-K regulatory

"no direct or indirect material interest in any existing or currently proposed transaction that would require disclosure under Item 404(a) of Regulation S-K"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Omeros Corporation (OMER) announce regarding its board on August 12, 2026?

Omeros Corporation’s board increased its size to nine directors and appointed Joseph Schocken as a new director effective August 12, 2026. His initial term extends until the 2027 annual meeting of shareholders, unless he resigns or is removed earlier.

Who is Joseph Schocken, the new director of Omeros Corporation (OMER)?

Joseph Schocken, 79, is a private investor and founder of Tranceka Capital, LLC. He previously founded Broadmark Capital LLC, helped create Broadmark Realty Capital, Inc., and currently serves as chairman of Taqtile, Inc., a digital work assistance platform.

What board committees will Joseph Schocken serve on at Omeros Corporation (OMER)?

Joseph Schocken has been appointed to the Audit Committee of Omeros Corporation’s Board of Directors. This committee oversees financial reporting and related internal controls as described in the company’s governance structure and supported by independent director participation.

What equity compensation is Joseph Schocken receiving as an Omeros (OMER) director?

Under Omeros’ non-employee director compensation policy, Joseph Schocken received a stock option to purchase 30,000 shares of common stock on his appointment date. This equity grant aligns with the company’s standard approach for compensating its outside directors.

Does Joseph Schocken have related-party transactions with Omeros Corporation (OMER)?

Omeros states that Joseph Schocken has no direct or indirect material interest in any existing or currently proposed transaction requiring disclosure under Item 404(a) of Regulation S-K. He is not party to any special arrangement connected to his board appointment.

How long will Joseph Schocken serve on the board of Omeros Corporation (OMER)?

Joseph Schocken’s initial term as a director will expire at Omeros’ 2027 annual meeting of shareholders. His service could end earlier if he resigns or is removed, consistent with the company’s standard governance provisions and director terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/13/2026 - 04:05 PM EDT Learn about SEC filing dates

false 0001285819 0001285819 2026-08-12 2026-08-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2026

OMEROS CORPORATION

(Exact name of Registrant as Specified in Its Charter)

Washington	001-34475	91-1663741
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
201 Elliott Avenue West Seattle, WA		98119
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 676-5000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.01 per share	OMER	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 under the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 12, 2026, the Board of Directors of Omeros Corporation (the “Company” or “we”), upon recommendation of the Nominating and Governance Committee of the Board of Directors, increased the number of its directors to nine and appointed Joseph Schocken as a director, effective immediately. Mr. Schocken’s initial term will expire at our 2027 annual meeting of shareholders or his earlier resignation or removal. The Board of Directors also appointed Mr. Schocken to the Audit Committee of the Board of Directors.

Mr. Schocken, 79, is a private investor and the founder and president of Tranceka Capital, LLC. Mr. Schocken founded Seattle-based investment bank Broadmark Capital LLC in 1987. In 2010, Mr. Schocken co-founded and served as chief executive officer of the entities that became Broadmark Realty Capital, Inc. (NYSE) until its merger in 2019. He served as its post-merger chairman from 2019 through 2021. He currently serves as chairman of Taqtile, Inc., a digital work assistance platform. Mr. Schocken has long been involved in politics and economic policy on a national level. He is recognized as one of the driving forces behind the JOBS Act, has testified on economic policy before committees of the U.S. House and Senate, and was a Presidential appointee to the National Advisory Council on Innovation and Entrepreneurship. He received his MBA from Harvard University and his BA in history from the University of Washington.

Pursuant to our non-employee director compensation policy, Mr. Schocken was granted a stock option to purchase 30,000 shares of our common stock on the date of his appointment. Mr. Schocken will be indemnified by the Company pursuant to the terms of our standard form of director indemnification agreement.

Mr. Schocken is not party to any understanding or arrangement in connection with his appointment as a director and has no direct or indirect material interest in any existing or currently proposed transaction that would require disclosure under Item 404(a) of Regulation S-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OMEROS CORPORATION
Date: August 13, 2026	By:	/s/ Gregory A. Demopulos
		Gregory A. Demopulos, M.D.
		President, Chief Executive Officer and
		Chairman of the Board of Directors

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB